558 related articles for article (PubMed ID: 11280786)
1. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
Slupianek A; Nieborowska-Skorska M; Hoser G; Morrione A; Majewski M; Xue L; Morris SW; Wasik MA; Skorski T
Cancer Res; 2001 Mar; 61(5):2194-9. PubMed ID: 11280786
[TBL] [Abstract][Full Text] [Related]
2. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
Nieborowska-Skorska M; Slupianek A; Xue L; Zhang Q; Raghunath PN; Hoser G; Wasik MA; Morris SW; Skorski T
Cancer Res; 2001 Sep; 61(17):6517-23. PubMed ID: 11522649
[TBL] [Abstract][Full Text] [Related]
3. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway.
Bai RY; Ouyang T; Miething C; Morris SW; Peschel C; Duyster J
Blood; 2000 Dec; 96(13):4319-27. PubMed ID: 11110708
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
5. Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas.
Colomba A; Courilleau D; Ramel D; Billadeau DD; Espinos E; Delsol G; Payrastre B; Gaits-Iacovoni F
Oncogene; 2008 Apr; 27(19):2728-36. PubMed ID: 17998938
[TBL] [Abstract][Full Text] [Related]
6. NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner.
Slupianek A; Skorski T
Exp Hematol; 2004 Dec; 32(12):1265-71. PubMed ID: 15588951
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.
Gu L; Gao J; Li Q; Zhu YP; Jia CS; Fu RY; Chen Y; Liao QK; Ma Z
Leukemia; 2008 Nov; 22(11):2091-6. PubMed ID: 18685609
[TBL] [Abstract][Full Text] [Related]
8. Genistein-induced apoptosis via Akt signaling pathway in anaplastic large-cell lymphoma.
Park SS; Kim YN; Jeon YK; Kim YA; Kim JE; Kim H; Kim CW
Cancer Chemother Pharmacol; 2005 Sep; 56(3):271-8. PubMed ID: 15883821
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.
Wasik MA; Zhang Q; Marzec M; Kasprzycka M; Wang HY; Liu X
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S27-35. PubMed ID: 19393833
[TBL] [Abstract][Full Text] [Related]
10. Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis.
Greenland C; Touriol C; Chevillard G; Morris SW; Bai R; Duyster J; Delsol G; Allouche M
Oncogene; 2001 Nov; 20(50):7386-97. PubMed ID: 11704868
[TBL] [Abstract][Full Text] [Related]
11. Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells.
McCubrey JA; Lee JT; Steelman LS; Blalock WL; Moye PW; Chang F; Pearce M; Shelton JG; White MK; Franklin RA; Pohnert SC
Cancer Detect Prev; 2001; 25(4):375-93. PubMed ID: 11531015
[TBL] [Abstract][Full Text] [Related]
12. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
[TBL] [Abstract][Full Text] [Related]
13. Opposite effects of Ha-Ras and Ki-Ras on radiation-induced apoptosis via differential activation of PI3K/Akt and Rac/p38 mitogen-activated protein kinase signaling pathways.
Choi JA; Park MT; Kang CM; Um HD; Bae S; Lee KH; Kim TH; Kim JH; Cho CK; Lee YS; Chung HY; Lee SJ
Oncogene; 2004 Jan; 23(1):9-20. PubMed ID: 14712206
[TBL] [Abstract][Full Text] [Related]
14. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
15. Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway.
Santos SC; Lacronique V; Bouchaert I; Monni R; Bernard O; Gisselbrecht S; Gouilleux F
Oncogene; 2001 Apr; 20(17):2080-90. PubMed ID: 11360192
[TBL] [Abstract][Full Text] [Related]
16. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
17. Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation.
Chikamori M; Fujimoto J; Tokai-Nishizumi N; Yamamoto T
Oncogene; 2007 May; 26(20):2950-4. PubMed ID: 17086210
[TBL] [Abstract][Full Text] [Related]
18. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.
Mitsuuchi Y; Johnson SW; Selvakumaran M; Williams SJ; Hamilton TC; Testa JR
Cancer Res; 2000 Oct; 60(19):5390-4. PubMed ID: 11034077
[TBL] [Abstract][Full Text] [Related]
19. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis.
Bischof D; Pulford K; Mason DY; Morris SW
Mol Cell Biol; 1997 Apr; 17(4):2312-25. PubMed ID: 9121481
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice.
Lange K; Uckert W; Blankenstein T; Nadrowitz R; Bittner C; Renauld JC; van Snick J; Feller AC; Merz H
Oncogene; 2003 Jan; 22(4):517-27. PubMed ID: 12555065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
